Patents by Inventor Weiqiang XING

Weiqiang XING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20240083886
    Abstract: Relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 14, 2024
    Inventors: Qinghua MENG, Weiqiang XING, Xichen LIN, Andrew JENNINGS
  • Heterocyclic GLP-1 agonists
    Patent number: 11926643
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: March 12, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Weiqiang Xing, Hui Lei, Andrew Jennings
  • Heterocyclic GLP-1 agonists
    Patent number: 11926626
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: September 21, 2022
    Date of Patent: March 12, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Weiqiang Xing, Haizhen Zhang, Xichen Lin, Hui Lei, Andrew Jennings
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230391760
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: October 13, 2021
    Publication date: December 7, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Xichen LIN, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230331732
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 19, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230322771
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 6, 2021
    Publication date: October 12, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • Phthalazinone compound, and preparation method therefor and medical use thereof
    Patent number: 11767312
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: September 26, 2023
    Assignee: GENENTECH, INC.
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20230242510
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Application
    Filed: April 5, 2023
    Publication date: August 3, 2023
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230174565
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: June 29, 2022
    Publication date: June 8, 2023
    Inventors: Qinghua MENG, Xichen LIN, Haizhen ZHANG, Weiqiang XING, Hui LEI, Andrew JENNINGS
  • PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20230131252
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 27, 2023
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION
    Publication number: 20230111119
    Abstract: Provided are a protein degradation agent compound preparation method and application; specifically, provided are the compound represented by formula (I) and a pharmacologically acceptable salt thereof, and an application of said compound in the degradation of androgen receptor (AR).
    Type: Application
    Filed: December 23, 2020
    Publication date: April 13, 2023
    Inventors: Hongfu LU, Weiqiang XING, Baojian QI, Jianbiao PENG, Haibing GUO
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230107793
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 21, 2022
    Publication date: April 6, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230071840
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 9, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20220213130
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 7, 2022
    Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Weiqiang Xing, Hui Lei, Andrew Jennings
  • AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE
    Publication number: 20220017513
    Abstract: Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Applicants: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD, JIANGXI JEMINCARE GROUP CO., LTD
    Inventors: Hongfu LU, Jianbiao PENG, Weiqiang XING, Haibing GUO
  • Compounds for inhibiting LRRK2 kinase activity
    Patent number: 11034696
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: June 15, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Feng Ren, Yingxia Sang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
    Patent number: 10975081
    Abstract: Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 13, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Yun Jin, Qian Liu, Feng Ren, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Hailong Wang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • Compounds
    Patent number: 10858367
    Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 8, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Feng Ren, Yingxia Sang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • COMPOUNDS
    Publication number: 20200079777
    Abstract: Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: July 22, 2016
    Publication date: March 12, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiao DING, Yun JIN, Qian LIU, Feng REN, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Hailong WANG, Weiqiang XING, Yang ZHAN, Baowei ZHAO
  • COMPOUNDS
    Publication number: 20190389850
    Abstract: The present invention provides novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: January 23, 2018
    Publication date: December 26, 2019
    Inventors: Feng REN, Yingxia SANG, Weiqiang XING, Yang ZHAN, Baowei ZHAO